by Jordana Choucair | Mar 28, 2022 | Life Sciences
The Food and Drug Administration (FDA) is expected to approve additional COVID-19 booster shots for adults over the age of 50 as early as next week. Once that happens, the Centers for Disease Control and Prevention (CDC) will likely make a “permissive recommendation,”...
by Jordana Choucair | Mar 23, 2022 | Life Sciences
The American Investment Council released a report indicating that private equity firms invested nearly $70 billion in the life sciences and medical device industries last year. Deals in both sectors reached the highest amount in a decade. Life sciences deal were worth...
by Jordana Choucair | Mar 23, 2022 | Life Sciences
Moderna Inc. said it will ask regulators to authorize its COVID-19 vaccine for children between 6 months and 6 years old. The drugmaker said that two clinical trials showed the shot generated a similar immune response as among young adults, though it was less...
by Jordana Choucair | Mar 23, 2022 | Life Sciences
AstraZeneca announced it has invested roughly $33 million in Huma, a U.K.-based medical technology start-up, as part of a broader commercial partnership between the two firms. The move will enable Huma, which develops remote patient monitoring systems, to expand...
by Jordana Choucair | Mar 22, 2022 | Life Sciences
The Food and Drug Administration (FDA) is ramping up in-person inspections of drug and device manufacturing facilities that were delayed during the pandemic. The FDA said it plans to return to a “normal cadence” next month for inspections overseas, where...
by Jordana Choucair | Mar 22, 2022 | Life Sciences
Pfizer Inc. said it struck a deal to sell up to 4 million courses of its COVID-19 antiviral pill at a “not-for-profit price” to the United Nations Children’s Fund, which will distribute the treatment to 95 lower-income countries. The drugmaker will...
Recent Comments